Amendola MA, Shirazi K, Amendola BE, Kuhns LR, Tisnado J, Yaghmai I. Computed tomography of malignant tumors          of the osseous pelvis. Comput.Radiol 1983;7:107-117.

Aubut JL, Mehta S, Cullen N, Teasell RW, ERABI Group, the SCIRE research team. A comparison of heterotopic         ossification treatment within the traumatic brain and spinal cord injured population: An evidence based         systematic review. Neuro Rehabil. 2011; 28: 151-160.

Banovac K, Gonzalez F, Wade N, Bowker JJ. Intravenous disodium etidronate therapy in spinal cord injury patients         with heterotopic ossification. Paraplegia 1993;31:660-666.

Banovac K, Gonzalez F, Evaluation and management of heterotopic ossification in patients with spinal cord injury.         Spinal Cord.1997;35:158-162.

Banovac K, Gonzalez F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord         Med.1997;20:60-65.

Banovac K, The effect of etidronate on late development of heterotopic ossification after spinal cord injury. The         Journal of Spinal Cord Medicine 2000;23:40-44.

Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with         indomethacin. Spinal Cord. 2001;39:370-374.

Banovac K, Williams JM, Patrick LD, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2         selective inhibitor (rofecoxib). Spinal Cord. 2004;42:707-710.

Buschbacher R, McKinley W, Buschbacher L, Devaney CW, Coplin B. Warfarin in prevention of heterotopic         ossification. Am J Phys Med Rehabil. 1992;71:86-91.

Chalmers J, Gray DH, Rush J. Observations on the induction of bone in soft tissues. J Bone Joint Surg Br.         1975;57:36-45.

Citak M, Suero EM, Backhaus M, Aach M, Godry H, Meindl R, Schildhauer TA. Risk factors for heterotopic ossification         in patients with spinal cord injury: A case-control study of 264 patients. Spine. 2012. 37(23), 1953-1957.

Durovic A, Miljkovic D, Brdareski Z, Plavsic A, Jevtic M. Pulse low intensity electromagnetic field as prophylaxis of         heterotopic ossification in patients with traumatic spinal cord injury. Vojnosanit Pregl 2009; 66: 22–28.

Finerman GA, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies         with EHPD. Metab Bone Dis Rel Res. 1981;3:337-342.

Fleisch H. Biphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and         metastatic bone disease. Drugs 1991;42:919-944.

Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in         tissue culture and in vivo. Sci. 1969;165:1262-1264.

Freed JH, Hahn H, Menter R, Dillon T. The use of the three-phase bone scan in the early diagnosis of heterotopic         ossification (HO) and in the evaluation of didronel therapy. Paraplegia 1982;208-216.

Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop Relat         Res 1989; 242: 169-276.

Garland DE, Alday B, Venos KG, and Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord         injury patients. Clinical orthopaedics and related research 1983;176:197-200.

Garland DE, Thompson R, Waters RL. Musculocutaneous neurectomy for spastic elbow flexion in non-functional         upper extremities in adults. J Bone Joint Surg Am. 1980;62:108-112.

Genet F, Jourdan C, Lautridou C, Chehensse C, Minooee K, Denormandie P, Schnitzler A. The Impact of         Preoperative Hip Heterotopic Ossification Extent on Recurrence in Patients with Head and Spinal Cord Injury: A         Case Control Study. PLoS ONE 2011; 6(8): e23129.

Hurvitz EA, Mandac BR, Davidoff G, Johnson JH, Nelson VS. Risk factors for heterotopic ossification in children and         adolescents with severe traumatic brain injury. Arch Phys Med Rehabil.1992;73:459-462.

Mavrogenis AF, Guerra G, Staals EL, Bianchi G, Ruggieri P. A classification method for neurogenic heterotopic         ossification of the hip. J Orthop Traumatol. 2012.13(2), 69-78.

Meiners T, Abel R, Bohm V, Gerner HJ. Resection of heterotopic ossification of the hip in spinal cord injured patients.         Spinal Cord .1997;35:443-445.

Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. A J Surg 2003;73:422-426.

Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med.         1985;26:125-132.

Pape HC, Lehmann U, van GM, Gansslen A, von GS, Krettek C. Heterotopic ossifications in patients after severe         blunt trauma with and without head trauma: incidence and patterns of distribution. J Orthop Trauma.         2001;15:229-237.

Pape HC, Marsh S, Morley JR, Krettek C, Giannoudis PV. Current concepts in the development of heterotopic         ossification. J Bone Joint Surg Br. 2004;86:783-787.

Puzas JE, Evarts CM, Brand JS. The stimulus for bone formation. Hip 1987;25-38.

Rossier AB, Bussat P, Infante F, Zender R, Courvoisier B, Muhelm G et al. Current facts of para-osteo-arthropathy         (POA). Paraplegia .1973;11(1):38-78.

Sautter-Bihl ML, Hultenschmidt B, Liebermeister E, Nanassy A Fractionated and single-dose radiotherapy for         heterotopic bone formation in patients with spinal cord injury. A phase-I/II study, Strahlenther Onkol 2001; 177:         200-205.

Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossifications in         patients with spinal cord injury. Spinal Cord. 2000;38:33-36.

Schurch B, Capaul M, Vallotton MB, Rossier AB. Prostaglandin E2 measurements: Their value in the early diagnosis         of heterotopic ossification in spinal cord injury patients. Arch Phys Med Rehabil. 1997;78(7):687-691.

Schuetz P, Mueller B, Christ-Crain M, Dick W, Haas H. Amino-biphosphonates in heterotopic ossification: first         experience in five consecutive cases. Spinal Cord. 2005;43:604-610.

Shehab D. Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med 2002;43:346-353.

Singh RS, Craig MC, Katholi CR, Jackson AB, Mountz JM. The predictive value of creatine phosphokinase and         alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury. Arch Phys         Med Rehabil. 2003;84(11):1584-1588.

Smith R. Fibrodysplasia (myositis) ossificans progressive. Clinical lessons learned from a rare disease. Clin Orthop.         1998;346:7-14.

Stover SL. Didtonel in the prevention of heterotopic ossification following spinal cord injury: Determination of an         optimal treatment schedule. Rehabil R D Prog Rep. 1987;25:110-111.

Subbarao JV, Nemchausky BA, Gratzer M, Hines E. Resection of heterotopic ossification and didronel therapy –         regaining wheelchair independence in the spinal cord injured patient. J AM Paraplegia Soc. 1987;10:3-7.

Teasell RW, Mehta S, Aubut JL, Ashe MC, Sequeira K, Macaluso S, Tu L, SCIRE research team. A systematic review of         the therapeutic interventions for heterotopic ossification after spinal cord injury. Spinal Cord. 2010; 48: 512-521.

Thomas BJ, Amstutz HC. Prevention of heterotopic bone formation: clinical experience with diphosphonates. Hip.         1987;59-69.

Tibone J, Sakimura I, Nickel VL, Hsu JD. Heterotopic ossification around the hip in spinal cord-injured patients. A         long-term follow-up study. J Bone Joint Surg Am. 1978;60(6):769-775.

van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic ossification in spinal cord injury. Spinal Cord.         2002;40:313-326.

Welch K, Goldberg D. Serum creatine phosphokinase in motor neuron disease. Neurol . 1973;22:697-701.

Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG. Cells isolated from adult human skeletal muscle         capable of differentiating into multiple mesodermal phenotypes. Am Surg . 1999;65:22-26.

Zychowicz ME. Pathophysiology of heterotopic ossification. Orthop Nurs 2013;32:173-177.